Le Lézard
Classified in: Health, Business
Subjects: LEG, SCZ, AVO

Medicare Advantage Offers Clues to Untangling the "Medicare for All" Dilemma

PITTSBURGH, July 9, 2019 /PRNewswire/ -- "Medicare for All" has become a confusing term among the existing 65+ year old Medicare population as they watch Congress debate universal health care, according to Patrick Phillips, CEO of Cavulus. Cavulus is a technology firm specializing in Medicare Advantage solutions.

Patrick Phillips, CEO Cavulus

Already in the 116th Congress more than 10 bills addressing "Medicare for All" have been introduced. Additionally, nationally televised debates among presidential hopefuls have tossed around even more ideas.

"Certainly, while a myriad of 'Medicare for All' proposals exist, the term essentially represents bills that propose a single-payer government run healthcare system seeking to replace public and private plans for people of all ages ? yet the majority of uninsured individuals in the U.S. are non-elderly (19-64)," Phillips explained.

Phillips believes "emerging policies should focus on those in need, rather than upending programs which tens of millions of seniors currently rely upon."

According to Phillips, the current Medicare program, specifically Medicare Advantage (MA), has emerged as one of the most stable aspects of the health insurance industry. He points to Fierce Healthcare studies revealing that roughly 10% of MA enrollees voluntarily switch plans on an annual basis compared to a 40% churn for adults enrolled under the Affordable Care Act (ACA).

"The attractiveness of Medicare Advantage is understandable given the robust medical and prescription drug coverage offered at competitive and predictable prices," asserts Phillips, noting Kaiser Family Foundation studies showing these prices to range from $26 per month for HMO enrollees to $45 per month for regional PPO enrollees. Moreover, there is also an easing of benefit design rules, so high-touch services such as transportation assistance, in-home care, and meal delivery are becoming standard.

"Rather than dismantling important programs such as CHIP, Medicaid, and Medicare," Phillips emphasizes, "there's already a solution within the public and private framework of the ACA if lawmakers were willing to approach it in a bipartisan way. The collaboration of regulatory oversight and private insurers in Medicare Advantage serves as a template the under-65 insurance market should mirror." 

Cavulus is a technology driven specialist in Medicare Advantage insurance solutions. The Cavulus Cloud-based Medicare Advantage Platform (Cavulus MAPtm) unifies marketing, sales and enrollment operations, and is utilized by some of America's top insurers, including several BlueCross/ BlueShield companies, UPMC Health Plan, SCAN Health Plan, John Hopkins Healthcare, Lumeris and United Healthcare. For details: visit www.cavulus.com.

Media Inquiries
Email: info@cavulus.com



SOURCE Cavulus

These press releases may also interest you

at 07:01
Halper Sadeh LLP, a global investor rights law firm, is investigating: Noble Energy, Inc.  concerning potential violations of the...

8 aoû 2020
LES Spine Innovations and Sagitechnology are proud to announce the launch of the new A-CIFT SoloFuse Hyperlordotic Cervical Standalone Interbody System, the first ever HA impregnated standalone cervical cage for greater sagittal correction. The...

8 aoû 2020
Symbria Inc. is pleased to announce that it is being featured in a nationally distributed television program, Behind the Scenes with Laurence Fishburne. Behind The Scenes is known for providing factual, unbiased information and specializes in mining...

8 aoû 2020
In lieu of an in-person update to the media, Dr. Theresa Tam, Canada's Chief Public Health Officer, issued the following statement today: "There have been 118,985 cases of COVID-19 in Canada, including 8,970 deaths. 87% of people have now recovered....

8 aoû 2020
The latest data of the evolution of COVID-19 in Québec reveal 126 new cases, bringing the total number of people infected to 60,367. During this same period, 4 new deaths were recorded, to which need to be added 1 death that occurred before July 31,...

8 aoû 2020
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, metabolic, autoimmune and other major diseases, today...

News published on 9 july 2019 at 10:08 and distributed by: